A community-based lifestyle intervention resulted in greater SBP reduction when compared with health education alone in hypertensive blacks, as observed in the FAITH randomized trial.
In a substudy of GLAGOV, IVUS-based virtual histology showed regression of coronary atherosclerosis in evolocumab-treated patients, but no changes in plaque composition as compared with placebo.
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes in patients with type 2 diabetes and chronic kidney disease at high CV risk.
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.
PCSK9-antibodies reduce non-cholesterol sterols but they do not significantly affect the balance between cholesterol synthesis and absorption, irrespective of cholesterol-lowering pretreatment.
Despite specific recommendations on its management in the 2016 ESC Heart Failure Guidelines, iron deficiency is insufficiently diagnosed and treated in clinical practice. Practical guidance is now provided to complement the ESC Guidelines.
Actuarial methods to estimate survival suggest that survival in T2DM patients with established CVD improves with empagliflozin compared with placebo.
The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.
Meta-analysis of individual-patient data shows that elevated Lp(a) levels of 50 mg/dL or higher were associated with an increased hazard ratio of CV events, independent of other risk factors and statin or placebo treatment.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
A new genomic score provides the opportunity to stratify individuals with different trajectories of CAD risk in general populations and to perform genomic screening in early life.
In patients with an established diagnosis of hypercholesterolemia, tocilizumab blunted the NSTEMI-associated PCSK9 increase and this was strongly correlated with a decrease in neutrophil numbers.